The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Mutant p53: A therapeutic target for the treatment of triple-negative breast cancer?
Naoise C. Synnott
No relevant relationships to disclose
Aisling Pierce
No relevant relationships to disclose
Maeve Mullooly
No relevant relationships to disclose
Francesco Caiazza
No relevant relationships to disclose
Patricia M. McGowan
No relevant relationships to disclose
Norma O'Donovan
No relevant relationships to disclose
John Crown
Honoraria - GlaxoSmithKline; Novartis; Pfizer; Roche; Sanofi
Research Funding - GlaxoSmithKline; Novartis; Pfizer; Roche; Sanofi
Michael J. Duffy
No relevant relationships to disclose